See more : Challenger Limited (CGF.AX) Income Statement Analysis – Financial Results
Complete financial analysis of MustGrow Biologics Corp. (MGROF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MustGrow Biologics Corp., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- Timken India Limited (TIMKEN.NS) Income Statement Analysis – Financial Results
- QuantaSing Group Ltd (QSG) Income Statement Analysis – Financial Results
- Dynagreen Environmental Protection Group Co., Ltd. (1330.HK) Income Statement Analysis – Financial Results
- NickelX Limited (NKL.AX) Income Statement Analysis – Financial Results
- Safari World PCL (SAFARI.BK) Income Statement Analysis – Financial Results
MustGrow Biologics Corp. (MGROF)
About MustGrow Biologics Corp.
MustGrow Biologics Corp., an agricultural biotech company, focuses om development and commercialization of natural biopesticide, biofumigants, and bioherbicides derived from mustard seed. It provides preplant soil biofumigation, a technology to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and other crops. The company is also developing bioherbicide to treat unwanted plant growth for use in organic agriculture, home, and garden markets, as well as agriculture markets; and postharvest food preservation, an application in sprout, disease, and pathogen treatment for storage and food preservation markets. In addition, it focuses on providing CannaPM, an active ingredient to treat fungal soil diseases, as well as foliar diseases. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.71M | 6.48K | 12.87K | 0.00 | 0.00 | 2.00K | 2.10K | 109.02K | 12.42K |
| Cost of Revenue | 384.69K | 298.21K | 203.59K | 187.68K | 74.19K | 44.74K | 48.71K | 21.26K | 75.80K |
| Gross Profit | 4.33M | -291.73K | -190.72K | -187.68K | -74.19K | -42.74K | -46.60K | 87.76K | -63.38K |
| Gross Profit Ratio | 91.84% | -4,502.72% | -1,482.03% | 0.00% | 0.00% | -2,136.90% | -2,217.13% | 80.50% | -510.45% |
| Research & Development | 857.07K | 475.86K | 458.38K | 149.25K | 83.00K | 13.54K | 749.00 | 21.26K | 75.80K |
| General & Administrative | 3.12M | 4.52M | 2.00M | 2.96M | 1.35M | 1.84M | 36.45K | 20.44K | 491.92K |
| Selling & Marketing | 558.60K | 696.82K | 567.93K | 263.55K | 36.47K | 9.49K | 0.00 | 0.00 | 0.00 |
| SG&A | 3.68M | 5.22M | 2.57M | 3.22M | 1.39M | 1.84M | 36.45K | 20.44K | 491.92K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.54M | 5.69M | 3.02M | 3.37M | 1.47M | 1.86M | 36.45K | 20.44K | 519.35K |
| Cost & Expenses | 4.92M | 5.69M | 3.02M | 3.37M | 1.47M | 1.86M | 36.45K | 20.44K | 595.15K |
| Interest Income | 211.60K | 103.55K | 3.32K | 45.87K | 45.88K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 10.07K | 52.77K | 45.87K | 45.88K | 40.24K | 27.31K | 0.00 | 0.00 |
| Depreciation & Amortization | -466.01K | 5.25M | 2.73M | 3.20M | 1.35M | 892.64K | 1.08K | 1.08K | 2.31K |
| EBITDA | -676.94K | 0.00 | 0.00 | 0.00 | 0.00 | -1.85M | -170.25K | -147.89K | -555.31K |
| EBITDA Ratio | -14.37% | -86,148.73% | -23,398.17% | 0.00% | 0.00% | -92,656.85% | -1,734.11% | -18.75% | -4,472.14% |
| Operating Income | -210.93K | -5.58M | -3.01M | -3.37M | -1.47M | -1.85M | -36.45K | -20.44K | -557.62K |
| Operating Income Ratio | -4.48% | -86,148.73% | -23,398.17% | 0.00% | 0.00% | -92,656.85% | -1,734.11% | -18.75% | -4,490.77% |
| Total Other Income/Expenses | -466.01K | -313.51K | -334.69K | -109.90K | -164.09K | -40.24K | 250.74K | 108.35K | -25.12K |
| Income Before Tax | -676.94K | -5.57M | -3.06M | -3.31M | -1.52M | -1.89M | -36.45K | -20.44K | -582.73K |
| Income Before Tax Ratio | -14.37% | -85,905.87% | -23,808.18% | 0.00% | 0.00% | -94,668.85% | -1,734.11% | -18.75% | -4,693.03% |
| Income Tax Expense | 0.00 | -5.24M | -2.73M | -3.15M | -1.35M | -161.14K | 88.55K | -24.40K | 0.00 |
| Net Income | -676.94K | -5.57M | -3.06M | -3.31M | -1.52M | -1.89M | -36.45K | -20.44K | -582.73K |
| Net Income Ratio | -14.37% | -85,905.87% | -23,808.18% | 0.00% | 0.00% | -94,668.85% | -1,734.11% | -18.75% | -4,693.03% |
| EPS | -0.01 | -0.11 | -0.07 | -0.09 | -0.06 | -0.08 | 0.00 | 0.00 | -0.03 |
| EPS Diluted | -0.01 | -0.11 | -0.07 | -0.09 | -0.06 | -0.08 | 0.00 | 0.00 | -0.03 |
| Weighted Avg Shares Out | 49.90M | 49.01M | 43.74M | 37.31M | 25.29M | 24.99M | 24.99M | 24.99M | 20.91M |
| Weighted Avg Shares Out (Dil) | 49.89M | 49.01M | 43.74M | 37.31M | 25.29M | 24.99M | 24.99M | 24.99M | 20.91M |
MustGrow Biologics moves to acquire agricultural products firm NexusBioAg
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) announced it has signed a non-binding term sheet with Univar Solutions Canada Ltd to acquire crop nutrition company NexusBioAg. The move aims to position MustGrow as a fully integrated provider of biological and regenerative agriculture...
MustGrow Biologics Signs Non-Binding Term-Sheet for Acquisition of NexusBioAg
Saskatoon, Saskatchewan--(Newsfile Corp. - November 27, 2024) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce the signing of a non-binding term-sheet (the "Term Sheet") dated November 27, 2024 with Univar...
MustGrow reports first revenue from TerraSante with major sales ramp-up forecasted for 2025
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) recognized revenue for sales of its biofertility product TerraSante for the first time in the third quarter with higher revenue generation on the horizon, analysts at Noble Capital believe. The agricultural technology company reported revenue...
MustGrow Biologics CEO discusses commercial expansion, Bayer partnership - ICYMI
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) CEO Corey Giasson joined Proactive to chat about the company's transition to commercialization from its R&D focus. He noted the commercialization of its biofertility product TerraSante, which has gained momentum in key US states.
MustGrow transitions to commercial TerraSante sales, prepares for 2025 ramp-up
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) is advancing its transition from research and development to commercialization with key developments across its biofertility and biopesticide products, the company said in a 2024 pipeline update. The company has begun manufacturing and selling its...
MustGrow Provides 2024 Pipeline Update
MustGrow transitions from R&D to commercialization. TerraSante TM biofertility product manufacturing and sales has commenced, with potential initial sales ramp-up in 2025 and 2026.
MustGrow secures funding for mustard seed research in collaboration with Agriculture and Agri-Food Canada
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) announced that it has received funding to investigate mustard-derived ingredient opportunities in human and animal health applications from Agriculture and Agri-Food Canada (AAFC). The funding has been provided through the AgriScience Program – Projects Component under...
MustGrow Receiving Funding from Agriculture and Agri-Food Canada for Human and Animal Health Applications
MustGrow will be receiving funding from Agriculture and Agri-Food Canada to investigate mustard-derived ingredient opportunities in human & animal health applications. Potential product opportunities may include application in functional foods and nutraceuticals for improved immunity and gut health in humans,...
MustGrow Biologics COO talks TerraSante's growth into Florida - ICYMI
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) COO, Colin Bletsky, talked with Proactive about the company's recent expansion into Florida with TerraSante, their innovative bio-fertility product. Following the earlier approval for California, Florida represents another significant market for MustGrow, as it is...
MustGrow East Coast expansion eyed by analysts following TerraSante approval in Florida
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) has secured approval for its mustard-based biofertility product TerraSante in a sixth state, with analysts at Noble Capital Markets expecting more approvals to come sooner rather than later. The company this week announced it has...
Source: https://incomestatements.info
Category: Stock Reports